The ELISA (Enzyme-Linked ImmunoSorbent Assay) test thus provides a new non-invasive method that can be used to determine the extent to which a population has been exposed to COVID-19, as well as to assess individual risk of infection.
The researchers, led by Dr Fernanda Ludolf of the Faculty of Medicine of the Brazilian Federal University of Minas Gerais, who published the paper in the journal Science Advances, said that the test can potentially be used to detect antibodies against coronavirus produced by vaccines.
The test was tested on 209 samples from 139 patients, two to 60 days after the onset of COVID-19 symptoms. The results were compared with the ELISA blood test of the same name. It was found that the urine test successfully detected antibodies in 187 samples, showing a sensitivity of 94% and specificity of 100%, compared to 88% and 100% respectively for the blood test.
Link to scientific publication https:/www.science.org/doi/10.1126/sciadv.abn7424
Source: CNA
Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source
